Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

被引：2
|
作者：
Gutierrez, M. E. [1 ]
Giaccone, G. [2 ]
Liu, S. V. [2 ]
Rajan, A. [3 ]
Guha, U. [3 ]
Halfdanarson, T. R. [4 ]
Curtis, K. K. [5 ]
Kunz, P. L. [6 ]
Gabrail, N. [7 ]
Hinson, J. M. [8 ]
Orlemans, E. O. [9 ]
机构：
[1] John Theurer Canc Ctr, Hematol & Oncol, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Canc Ctr, Hematol & Oncol, Washington, DC USA
[3] NCI, Thorac & Gastrointestinal Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[4] Mayo Clin, Med, Rochester, MN USA
[5] Mayo Clin, Internal Med, Scottsdale, AZ USA
[6] Stanford Univ, Sch Med, Med Oncol, Palo Alto, CA 94304 USA
[7] Gabrail Canc Ctr, Hematol, Canton, OH USA
[8] Unicorn Pharma Consulting, Clin Res, Nashville, TN USA
[9] Esanex Inc, Clin Res, Indianapolis, IN USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw369.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs)
    Gutierrez, Martin E.
    Giaccone, Giuseppe
    Liu, Stephen V.
    Rajan, Arun
    Guha, Udayan
    Halfdanarson, Thorvardur
    Kunz, Pamela
    Hinson, James M., Jr.
    Orlemans, Everardus O.
    PANCREAS, 2018, 47 (03) : 339 - 339
  • [2] A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.
    Gutierrez, Martin
    Giaccone, Giuseppe
    Harper, Harry D.
    Liu, Stephen V.
    Fang, Bruno
    Ruiz, Jimmy
    Hinson, James M.
    Orlemans, Everardus Otto
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
    Bryson, J. C.
    Infante, J. R.
    Ramanathan, R. K.
    Jones, S. F.
    Von Hoff, D. D.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
    Infante, Jeffrey R.
    Weiss, Glen J.
    Jones, Suzanne
    Tibes, Raoul
    Bauer, Todd M.
    Bendell, Johanna C.
    Hinson, James M., Jr.
    Von Hoff, Daniel D.
    Burris, Howard A., III
    Orlemans, Everardus O.
    Ramanathan, Ramesh K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2897 - 2904
  • [5] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [6] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [7] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors
    Angevin, Eric
    Elez, Elena
    Cohen, Steven J.
    Van Laethem, Jean-Luc
    Ottensmeier, Christian
    Joly, Florence
    Ray-Coquard, Isabelle
    Lopez-Martin, Jose A.
    Dirix, Luc
    Machiels, Jean-Pascal
    Clive, Sally
    Steven, Neil Matthew
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas
    Bandekar, Rajesh
    Van de Velde, Helgi
    Tromp, Brenda J.
    Vermeulen, Jessica
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [10] CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY
    Stemmer, S. M.
    Benjaminov, O.
    Medalia, G.
    Ciuraru, N. B.
    Silverman, M. H.
    Bar-Yehuda, S.
    Fishman, S.
    Harpaz, Z.
    Farbstein, M.
    Cohen, S.
    Patoka, R.
    Singer, B.
    Kerns, W. D.
    Fishman, P.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S555 - S555
12345